CYCC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CYCC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cyclacel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $8.81 Mil.
During the past 12 months, Cyclacel Pharmaceuticals's average Total Assets Growth Rate was -44.10% per year. During the past 3 years, the average Total Assets Growth Rate was 16.90% per year. During the past 5 years, the average Total Assets Growth Rate was 25.80% per year. During the past 10 years, the average Total Assets Growth Rate was 5.10% per year.
During the past 13 years, Cyclacel Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 49.70%. The lowest was -51.40%. And the median was -0.20%.
Total Assets is connected with ROA %. Cyclacel Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 was -197.95%. Total Assets is also linked to Revenue through Asset Turnover. Cyclacel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.
The historical data trend for Cyclacel Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Assets | Get a 7-Day Free Trial | 15.31 | 36.80 | 43.14 | 28.05 | 8.81 |
Cyclacel Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Total Assets | Get a 7-Day Free Trial | 28.05 | 22.06 | 16.44 | 12.50 | 8.81 |
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Cyclacel Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (A: Dec. 2023 ) | + | Total Liabilities (A: Dec. 2023 ) |
= | 0.607 | + | 8.198 | |
= | 8.81 |
Cyclacel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 is calculated as
Total Assets | = | Total Equity (Q: Dec. 2023 ) | + | Total Liabilities (Q: Dec. 2023 ) |
= | 0.607 | + | 8.198 | |
= | 8.81 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclacel Pharmaceuticals (NAS:CYCC) Total Assets Explanation
Total Assets is connected with ROA %.
Cyclacel Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2023 is
ROA % | = | Net Income (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | -21.084 | / | ( (12.497 | + | 8.805) | / 2 ) | |
= | -21.084 | / | 10.651 | ||||
= | -197.95 % |
Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Cyclacel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
Asset Turnover | ||||||
= | Revenue (Q: Dec. 2023 ) | / | ( (Total Assets (Q: Sep. 2023 ) | + | Total Assets (Q: Dec. 2023 )) | / count ) |
= | 0.031 | / | ( (12.497 | + | 8.805) | / 2 ) |
= | 0.031 | / | 10.651 | |||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Spiro Rombotis | director, officer: President & C.E.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Paul Mcbarron | director, officer: E.V.P., Finance & C.O.O. | C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922 |
Kenneth M. Ferguson | director | 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121 |
Sam L Barker | director | 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525 |
Brian Schwartz | director | C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803 |
Karin L Walker | director | C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Mark Kirschbaum | officer: Chief Medical Officer | 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018 |
Robert J. Spiegel | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Eastern Capital Ltd | 10 percent owner | 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kevin C Tang | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Partners Lp | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Tang Capital Management Llc | 10 percent owner | 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
Portfolio Services Ltd. | 10 percent owner | 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006 |
Kenneth Bryan Dart | 10 percent owner | P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206 |
Lloyd Sems | director | C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017 |
From GuruFocus
By sperokesalga sperokesalga • 02-27-2023
By GlobeNewswire • 11-28-2023
By Marketwired • 08-09-2023
By sperokesalga sperokesalga • 05-04-2023
By Value_Insider Value_Insider • 12-15-2022
By Marketwired • 08-03-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By Value_Insider Value_Insider • 11-09-2022
By PurpleRose PurpleRose • 07-12-2022
By GuruFocusNews GuruFocusNews • 06-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.